Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma. Notified -
Zoom AI Companion 3.0 Empowers Workers to Reclaim Time, Backed by New Research on Lost Lunch Breaks Notified -
GetYourGuide Launches Global Brand Campaign "Book Forward to It," Reframing How Travelers Think About Planning Notified -
YY Group Holding Announces Estimated Total Assets and Net Assets per Share of $8.03 and $3.18, Respectively, for Fiscal Year 2025 Notified -
Urban-Gro Positioned to Capture Growth as T20 Cricket Franchise Valuations Exceed $1.6 Billion and Global Media Expansion Accelerates Notified -
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care Notified -
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025 Notified -
